Wilson's Advisory, today. We maintain our OVERWEIGHT rating on...

Wilson's Advisory, today.
We maintain our OVERWEIGHT rating on Clarity Pharmaceuticals and increase our risked PT to $3.12/sh (unrisked $7.71/sh). Clarity have recently completed a $110M institutional equity placement and entitlement offer (with ongoing retail component) that will see them funded through
to CY26 including major trial programs for their PSMA directed assets (64Cu/67Cu-SAR-bisPSMA) as they progress through Phase II & Phase III. Removal of funding overhang from the stock will be supportive of SP momentum given Clarity still have plenty of data yet to share this year with their
SABRE trial, focused on non-PSMA avid prostate cancer diagnosis, the next big catalyst in the coming months. Meanwhile, interest from big pharma in the Radiopharma space continues with AstraZeneca the latest to join the arena acquiring Fusion Pharmaceuticals and their Phase II alphaemitter PSMA Tx asset and pipeline. We clearly note the consistent inclusion of manufacturing capabilities as part of these acquisitions. Clarity have that part of the equation now further solidified with their extended agreement with NorthStar for end product cGMP manufacture of their 67CuSAR-bisPSMA therapeutic agent – continuing to make CU6 a standout target – one that is highly complementary to any alpha-focused Tx portfolio.